CWM
AKBA icon

CIBC World Markets’s Akebia Therapeutics AKBA Stock Holding History

CIBC World Markets’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		$27K Buy
+16,752
New +$35.1K ﹤0.01% 1221
2025
Q2 		$112K Sell
30,804
-17,245
-36% -$47.4K ﹤0.01% 1386
2025
Q1 		$92.3K Buy
48,049
+28,581
+147% +$58.3K ﹤0.01% 1618
2024
Q4 		$37K Buy
+19,468
New +$33.8K ﹤0.01% 1283

Other funds holding AKBA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Citigroup
Citigroup New York $235B AUM 32.99% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

CIBC World Markets's AKBA Position: Q4 2025 in Review

CIBC World Markets opened a new position in Akebia Therapeutics (AKBA) in Q4 2025: 16,752 shares worth $27K. The stake represents ﹤0.01% of the portfolio and ranks #1221 among its holdings. This is a return to the name: CIBC World Markets previously reported a position in AKBA as recently as Q2 2025.

CIBC World Markets first reported a position in AKBA in Q4 2024 and has held it in 4 quarters since. The position peaked at $112K in Q2 2025. 165 funds tracked by Wall St. Rank hold AKBA as of Q4 2025.

  • CIBC World Markets held 16,752 shares of Akebia Therapeutics worth $27K as of Q4 2025.
  • Akebia Therapeutics was a new CIBC World Markets position in Q4 2025.
  • Akebia Therapeutics made up ﹤0.01% of CIBC World Markets's portfolio in Q4 2025, its #1221 holding.
  • CIBC World Markets first reported a position in Akebia Therapeutics in Q4 2024 and has held it in 4 quarters since.
  • CIBC World Markets's Akebia Therapeutics position peaked at $112K in Q2 2025.
  • 165 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q4 2025.

Based on CIBC World Markets's 13F filing for Q4 2025, filed 12 Feb 2026.